

Regd. Office :
'Zydus Tower',
Satellite Cross Roads,
Ahmedabad 380 015. India.
Phone : +91-79-2686 8100 (20 Lines)
Fax : +91-79-2686 2368
www.zyduscadila.com
CIN:L24230GJ1995PLC025878

August 8, 2017

BSE Limited
1st Floor, P J Towers,
Dalal Street,
Mumbai – 400 001

National Stock Exchange of India Limited
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (East),
Mumbai – 400 051

Re.: Press Release

Dear Sir / Madam,

We enclose herewith a copy of press release dated August 8, 2017 titled "Zydus receives tentative approval from the USFDA for Abacavir and Lamivudine Tablets USP".

The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking You,

Yours faithfully,
For, **CADILA HEALTHCARE LIMITED**



UPEN H. SHAH
COMPANY SECRETARY

Zydus receives tentative approval from the USFDA for Abacavir and Lamivudine Tablets USP

Ahmedabad, 8 August 2017

Zydus Cadila has received the tentative approval from the USFDA to market Abacavir and Lamivudine Tablets USP, 600 mg/300 mg. The drug is indicated for use in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus (HIV) infection and will be produced at the group's formulations manufacturing facility at the Pharma SEZ in Ahmedabad.

The sales of Abacavir and Lamivudine Tablets is estimated at \$240.2 million. *Source: IMS Health, IMS National Sales Perspective Audit, MAT June 2017, extracted August 2017.*

The group now has more than 130 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.
